Personalized and Precision Medicine Journal

Abstract PAI-1 has become recognized as a central molecule linking pathogenesis and progression of thrombotic vascular events, including stroke. Clinical and experimental studies show that PAI-1 deficiencies cause accelerated fibrinolysis and bleeding, whereas elevated PAI-1 plasma levels are associated with vascular thrombosis. Raised PAI1 plasma levels are related to a 1-bp guanine deletion/insertion (4G/5G) polymorphism in the promoter of the PAI1 gene. The 4G allele is associated with higher plasma PAI1 transcription and activity. In the current study, the association of higher PAI-1 plasma levels and the prevalence of the 4G/5G polymorphism in the PAI-1 gene promoter region in young patients with stroke were explored. Significantly, higher PAI-1 levels were observed in patients when compared to controls (p =002). The 4G/5G polymorphisms were significantly associated with increased PAI-1 levels, with the variant homozygous 4G/4G corresponding to mean values in patients versus controls.

Abstract Cervical cancer is the second most common cancer and an important cause of death in women worldwide. Objective biomarkers are needed to improve specificity for cervical cancer screening. The p16 gene is implicated in the cell cycle control, playing an important role as a tumor suppressor gene. In this study, the methylation of the P16 gene promoter was evaluated in people with cervical cancer and people with the papilloma virus. The study population included nine women with cervical cancer whose malignancy had been confirmed by a pathologist and ten patients with high-risk types of HPV virus. Methylation status was evaluated by MS-PCR. Cervical cancer patients showed a significantly higher methylation frequency for the p16 gene as compared to the control and the HPV group (p=0.001).